Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionAlpha Teknova Inc. Common Stock (TKNO)
Fair value
Not available
ACCE price target
$4.60
Rating
Not rated
Horizon
12 months
ACCE price target published on 22 Oct 2026, 01:52 CEST; previously $6.10 since 15 Oct 2026, 00:00 CEST.
Price used: $6.42 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
47
out of 100
Analysts
88% buy
8 covering
1-year return
+11.5%
Dividend yield
0.00%
Alpha Teknova Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Alpha Teknova makes specialty and generic drug products, and the data gives me no detail beyond that industry label, so any claim about its specific molecules or manufacturing sites would be guesswork. What the numbers show is a $408M company growing revenue 18.5% with a 34.6% gross margin, but an operating margin of -23.7% and a return on equity of -24.2%, so the business is not yet covering its costs. With a trailing and forward P/E of zero, earnings are not a usable valuation anchor, which leaves the investment case resting on whether the top-line growth can convert into operating leverage. The score of 50/100 and absence from any index suggest the market has not yet rewarded the growth. It is worth a deeper look only if the next filings show operating losses narrowing as revenue scales.